Insmed Incorporated (NASDAQ:INSM) on Thursday reported 12-month results from the ongoing open-label extension (OLE) study of its once-daily treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) patients.
PAH is a rare, progressive disease where the tiny arteries in the lungs narrow, increasing blood pressure and forcing the heart to work harder.
Sustained Efficacy Seen Across Key Clinical Measures The company said the data showed sustained improvements across multiple efficacy measures and similar benefits among patients who switched from placebo to TPIP, reinforcing its confidence as the Phase 3 PALM-PAH trial moves forward.
The OLE study was designed to assess the long-term safety, tolerability, and effectiveness of TPIP over 24 months in patients who completed earlier TPIP PAH studies.
The non-placebo-controlled trial enrolled patients who either continued TPIP treatment or crossed over from placebo.
